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Comparison of Post-injection Site Pain Between Technetium
Sulfur Colloid and Technetium Tilmanocept in Breast Cancer
Patients Undergoing Sentinel Lymph Node Biopsy
Jonathan T. Unkart, MD1, Jennifer L. Baker, MD1, Ava Hosseini, MD1, Carl K. Hoh, MD2, Mark S. Wallace, MD3,
David R. Vera, PhD2,4, and Anne M. Wallace, MD1
1Department of Surgery, University of California, San Diego, La Jolla, CA ; 2Department of Radiology, University of
California, San Diego, La Jolla, CA; 3Department of Anesthesia, University of California, San Diego, La Jolla, CA;
4Molecular Imaging Program, University of California, San Diego, La Jolla, CA
ABSTRACT
Background. No prior studies have examined injection
pain associated with Technetium-99m Tilmanocept
(TcTM).
Methods. This was a randomized, double-blinded study
comparing postinjection site pain between filtered Tech-
netium Sulfur Colloid (fTcSC) and TcTM in breast cancer
lymphoscintigraphy. Pain was evaluated with a visual
analogue scale (VAS) (0–100 mm) and the short-form
McGill Pain Questionnaire (SF-MPQ). The primary end-
point was mean difference in VAS scores at 1-min
postinjection between fTcSC and TcTM. Secondary end-
points included a comparison of SF-MPQ scores between
the groups at 5 min postinjection and construction of a
linear mixed effects model to evaluate the changes in pain
during the 5-min postinjection period.
Results. Fifty-two patients underwent injection (27-
fTcSC, 25-TcTM). At 1-min postinjection, patients who
received fTcSC experienced a mean change in pain of
16.8 mm (standard deviation (SD) 19.5) compared with
0.2 mm (SD 7.3) in TcTM (p = 0.0002). At 5 min
postinjection, the mean total score on the SF-MPQ was 2.8
(SD 3.0) for fTcSC versus 2.1 (SD 2.5) for TcTM
(p = 0.36). In the mixed effects model, injection agent
(p\ 0.001), time (p\ 0.001) and their interaction
(p\ 0.001) were associated with change in pain during the
5-min postinjection period. The model found fTcSC
resulted in significantly more pain of 15.2 mm (p\ 0.001),
11.3 mm (p = 0.001), and 7.5 mm (p = 0.013) at 1, 2, and
3 min postinjection, respectively.
Conclusions. Injection with fTcSC causes significantly
more pain during the first 3 min postinjection compared
with TcTM in women undergoing lymphoscintigraphy for
breast cancer.
Sentinel lymph node (SLN) biopsy is the standard pro-
cedure for axillary staging in breast cancer patients with
clinically negative lymph nodes. Technetium sulfur colloid
(TcSC) is the most commonly used radiotracer for SLN
biopsy in breast cancer around the United States. Receiving
an injection of TcSC preoperatively is known to cause
considerable injection site pain.1 Prior studies have
explored various methods to decrease pain associated with
TcSC injection with mixed results. A study by Stojadinovic
et al. demonstrated that adding lidocaine to a mixture with
TcSC decreased injection site pain; however, a study by
O’Connor et al. found no benefit of applying topical
anesthetics before TcSC injection.2,3
Technetium-99m tilmanocept (TcTM), a recently FDA-
approved radiopharmaceutical designed for SLN identifi-
cation, travels through lymphatics and binds to the CD206
receptor within macrophages present in lymphatic tissue.4,5
During preapproval clinical trials at our institution, nuclear
medicine technicians and radiology staff anecdotally
observed that patients undergoing TcTM injection reported
less pain compared with patients undergoing injection with
filtered TcSC (fTcSC).6,7 Pain with TcTM injection has not
previously been studied in the literature.
The primary goal of this study was to assess the dif-
ference in the amount of injection site pain experienced by
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breast cancer patients after receiving an injection of fTcSC
versus TcTM prior to SLN imaging and biopsy.
METHODS
Patients
This was a randomized, double-blinded, single-institu-
tion, controlled clinical trial comparing postinjection site
pain of fTcSC versus TcTM in breast cancer patients
scheduled to undergo SLN biopsy. Before initiation,
Institutional Review Board approval was obtained and the
trial was registered at clinicaltrials.gov (NCT02065232).
Female patients, aged C18 years with a diagnosis of pri-
mary breast cancer or ductal carcinoma in situ (DCIS) with
planned SLN biopsy as part of the surgical plan were
approached at preoperative clinic visits of the principal
investigator (AMW). Pregnant patients, patients undergo-
ing bilateral SLN biopsy, or patients with clinical and/or
radiological evidence of metastatic lymph nodes or sys-
temic disease were excluded.
Data on patient age, body mass index (BMI), race,
history of diabetes, history of daily narcotic use, cancer
treatment involving neoadjuvant chemotherapy or endo-
crine therapy, use of preoperative needle localization for
guided surgical resection, and injecting radiologist were
recorded.
Randomization
Randomization was performed by the Department of
Biostatistics at the UCSD Clinical and Translational
Research Institute (CTRI). Patients were allocated in 1:1
ratio between fTcSC and TcTM. After a patient consented
to the study, the Clinical Trials Office (CTO) assigned a
study number to the patient corresponding to either of the
two groups. The CTO facilitated ordering of the proper
solution for injection with the nuclear technician such that
both the radiologist and the operating team were blinded to
the pharmaceutical agent injected.
Radiopharmaceutical Preparation
Both Technetium-99m Sulfur Colloid and TcTM were
prepared according to manufacturer package inserts (TcSC-
Pharmulence Inc., Billeria, MA, TcTM-Navidea Pharma-
ceuticals, Dublin, OH) by a centralized radiopharmacy
(Cardinal Health, San Diego CA). The TcSC preparation
was filtered (100 nm) by a standard Cardinal Health pro-
tocol to produce filtered Technetium-99m Sulfur Colloid
(fTcSC). The pH of the study agents was checked period-
ically and found to be 6.0 for both fTcSC and TcTM. The
study agents were delivered in a 27-gauge insulin syringe
with a label that hid the agent identification (the correct
drug was verified by the pharmacist, the CTO, and nuclear
technician prior to handing the drug to the injecting radi-
ologist with the blinded label).
Injection
Patients received a 0.1-ml solution (0.36–0.55 mCi) of
either fTcSC or TcTM. The patient and radiologist
administering the agent were blinded to the injection drug.
The injection was performed utilizing a single, intradermal
injection overlying the biopsy area or tumor by one of two
nuclear medicine radiologists. Immediately before injec-
tion, an alcohol swab was used to clean the injection site.
The injection time was standardized for 5 s and intradermal
injection was confirmed by presence of a skin wheal.
Background of Pain Questionnaires
The visual analog scale (VAS) is a measure of pain
intensity.8 Operationally, the VAS is a horizontal line,
100 mm in length, anchored by word descriptors at each
end. The left and right ends are labeled ‘‘no pain’’ and
‘‘worst possible pain,’’ respectively. The patient is
instructed to make a vertical mark on the horizontal line
that they feel represents their pain intensity. The VAS is
scored manually by measuring in millimeters from the left
hand end of the line to the point that the patient marks. The
short-form McGill Pain Questionnaire (SF-MPQ) is a val-
idated pain survey designed to measure the sensory and
affective quality of pain.9 The survey consists of 15
descriptors (11 sensory and 4 affective) that may charac-
terize the patient’s quality of their pain. Each descriptor is
given a rating of 0–3 corresponding to the patient’s
response of none, mild, moderate, or severe. The scores for
each descriptor are added such that each patient has a
sensory score rated from 0 to 33, an affective score rated 0
to 12, and a combined score rated 0 to 45.
Pain Survey Administration
The VAS and SF-MPQ were administered during the
study. The VAS was administered immediately preinjec-
tion and then at 1-, 2-, 3-, 4-, and 5-min postinjection time
points. The SF-MPQ was administered immediately
preinjection and then at 5 min postinjection. At the 5-min
time point, the patients were instructed to answer the SF-
MPQ based on the experience during the time encom-
passing injection and the 5 min after injection, whereas at
preinjection they were instructed to answer based on their
current pain. The individual administering the pain surveys
was blinded to the study agent. A stopwatch was used to
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keep track of time postinjection and the clock was started
when the needle was removed from the patient’s skin.
Preoperative Needle Localization Procedure
For patients scheduled to undergo breast conservation
(BCT) surgery, standard practice at our institution is for our
breast radiologists to place needles under ultrasound,
mammographic, or MRI guidance to aid with surgical
resection a few hours prior to planned surgical resec-
tion. The procedure is performed in the radiology suite, and
when concluded, the patient is immediately brought to the
nuclear medicine room for the lymphoscintigraphy
procedure.
Endpoints
The primary endpoint of this study was the assessment
of mean changes in VAS pain scores at 1 min postinjection
(VASt=1min - VASt=0min) between fTcSC and TcTM.
Secondary endpoints included comparison of mean VAS
pain scores in the first 5 min postinjection as well as dif-
ferences in sensory and affective experiences as captured
by the SF-MPQ at 5 min postinjection between the two
groups.
Sample Size Determination and Statistical Analysis
Calculation of sample size was performed using the
assumption that the minimal clinically significant change in
VAS score is 13 mm with an expected standard deviation
of 12.10 Controlling for probability of a type 1 error,
(a) = 0.01 and power (1 - b) = 0.9, 52 total patients (26
per group) were needed to detect no difference between
groups. Trial end was set when a total of 52 patients
enrolled and completed the lymphoscintigraphy procedure.
For our primary endpoint, a two-sample t test was used
to assess mean differences in pain score changes on the
VAS scale at 1 min postinjection between fTcSC and
TcTM. The 5-min SF-MPQ scores were analyzed using a
two-sample t test to assess mean differences between the
groups. Baseline patient characteristics were analyzed with
ANOVA for continuous variables or Fisher’s exact test/Chi
squared tests for categorical variables.
To assess pain differences between the groups over the
first 5 min postinjection, we fit a linear mixed-effects
model (LMM). The LMM is a random coefficient model
that takes both baseline heterogeneity and time-variant
effects into consideration by incorporating the subject-
specific intercept and slope. The form of the model is as
follows: Yij = b0 ? b
TXij ? ui
TZi ? eij where Yij is the
change in pain for patient i between minute j and baseline,
b0 is a shared intercept term, b
T represents the transpose of
the vector whose elements are values of the fixed effects
(group, time, their interaction, use of needle localization,
and baseline score), Xij is the design matrix for the fixed
effects, ui
T represents the transpose of the vector containing
the random effects associated with each patient (following
a multivariate normal distribution with mean 0 and vari-
ance matrix Ru
2), Zi is the design matrix for the random
effects, and eij is a normal distributed error term with mean
0 and variance r2. The difference of pain change between
two groups for each minute is reported by using contrast
tests with approximate normal distribution. The signifi-
cance level of the contrast tests is adjusted by using the
Holm–Bonferroni method to control for false discovery
rate for multiple comparisons.11
Statistical analysis was performed using R (v3.1.2)
software under supervision of the UCSD CTRI. A p value
\0.05 was considered statistically significant
RESULTS
Between March 2014 and February 2015, 57 patients
were enrolled and provided written consent to participate in
the study. A participant flow sheet is seen in Fig. 1. Fifty-
two women underwent successful radiopharmaceutical
injection and completed the pain surveys, 27 for fTcSC,
and 25 for TcTM. Of the five patients who did not undergo
study completion, three patients withdrew prior to the
procedure, one patient’s treatment plan changed to not
include SLN biopsy, and one patient received an incorrect
dose of a study agent. There were no statistically signifi-
cant differences in baseline patient characteristics between
the two groups (Table 1).
Pain at 1 Minute PostInjection
At 1 min postinjection, patients receiving fTcSC expe-
rienced a statistically significant higher change in mean
pain of 16.8 mm (standard deviation (SD) 19.5) compared
with 0.2 mm (SD 7.3) in TcTM (p = 0.0002). Individual
pain scores at 1 min postinjection are depicted in Fig. 2.
SF-MPQ at 5 Min Postinjection
At 5 min postinjection, there was no statistically sig-
nificant difference in SF-MPQ pain scores between the
groups. The mean total score on the SF-MPQ was 2.8 (SD
3.0) in fTcSC versus 2.1 (SD 2.5) for TcTM (p = 0.36).
Pain During Initial 5 Min Postinjection
In our final LMM, injection agent (p\ 0.001), time
(p\ 0.001), and their interaction (p\ 0.001) were found
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to be significantly associated with change in pain over the
5 min postinjection period. Preoperative needle localiza-
tion (p = 0.26) and baseline pain scores (p = 0.17) were
not a significant predictor of changes in pain score. The
final model with pain score predictions over the first 5 min
postinjection is depicted in Fig. 3. Furthermore, the model
found fTcSC resulted in significantly more pain of
15.2 mm (p\ 0.001), 11.3 mm (p = 0.001), and 7.5 mm
(p = 0.013) at 1, 2, and 3 min postinjection, respectively
(Table 2). Differences at 4 and 5 min postinjection were
not statistically significant.
DISCUSSION
Our study is the first to evaluate the difference in pain
experienced by patients receiving either an injection of
fTcSC versus TcTM. We found that patients receiving
fTcSC experience statistically significantly more pain
than those receiving TcTM at 1 min postinjection.
Additionally, our LMM incorporating pain scores from
the VAS scale demonstrates that patients receiving
fTcSC experience significantly more pain during the
initial 3 min postinjection compared with TcTM. While
the majority of the patients experienced a mild amount
of discomfort, a few patients reached the moderate range
([40 mm change) in the fTcSC, whereas none of the
subjects in the TcTM group reached the moderate range.
Total pain scores utilizing the SF-MPQ did not differ
between groups preinjection or at the 5-min postinjection
time points. Although the patients were instructed to
answer based on their experience over the previous 5-min
postinjection period, at 5 min the majority of patients had
stopped experiencing any pain above baseline in either
group and the SF-MPQ may have not adequately reflected
their peak pain experience. Additionally, while the SF-
MPQ has an affective domain that measures distress
associated with the injection, with the pain lasting for such
57 patients consented for
SLN biopsy and study
29 assigned
fTcSC
3
excluded
27
analyzed
for pain
25
analyzed
for pain
2
excluded
28 assigned
TcTM
FIG. 1 Patient flow diagram. SLN
sentinel lymph node; fTcSC filtered
Technetium-99m Sulfur Colloid; TcTM
Technetium-99m Tilmanocept
TABLE 1 Baseline patient characteristics
fTcSC
(n = 27)
TcTM
(n = 25)
p value*
Age (years) 56.0 ± 10.4 56.9 ± 12.7 0.80
BMI (kg/m2) 26.0 ± 5.4 26.1 ± 5.8 0.94
Race
White 21 23 0.23
Asian 3 2
Hispanic 3 0
Diabetes 1 0 1.00
Daily narcotic use 1 2 1.00
Neoadjuvant treatment
Chemotherapy 6 5 0.30
Endocrine 3 0
Preoperative needle
localization
18 16 1.00
Radiologist
#1 13 7 0.16
#2 14 18
Preinjection VAS score
(mm)
9.0 ± 16.0 9.0 ± 14.1 1.00
SF-MPQ preinjection score 1.9 ± 3.4 1.7 ± 2.9 0.88
Data are presented as mean ± standard deviation or numbers unless
otherwise indicated
fTcSC filtered Technetium-99m Sulfur Colloid; TcTM Technetium-
99m Tilmanocept, VAS visual analogue scale; SF-MPQ short-form
McGill Pain Questionnaire
* ANOVA or v2/Fisher’s exact test
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a short duration, we would not expect to see any distress
even with pain that reaches moderate levels.
Several studies have verified that injection of TcSC
formulations prior to lymphoscintigraphy is painful and
have evaluated ways to minimize the pain associated with
TcSC injection. Stojadinovic et al. examined a variety of
techniques that involved addition of local anesthetic and
sodium bicarbonate to TcSC. They found that adding 1 %
lidocaine decreased patient pain, but changing pH did not
alter pain scores.2 Hawkins et al. found that a separate
injection of lidocaine prior to intradermal injection with
TcSC decreased patient pain.12 Another study by O’Connor
et al. had patients apply topical anesthetic creams prior to
TcSC injection.3 They did not find benefit with the
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FIG. 3 Linear mixed-effects model. fTcSC filtered Technetium-99m Sulfur Colloid; TcTM Technetium-99m Tilmanocept. This figure represents
the final linear mixed-effects model that incorporates injection agent, time, injection 9 time interaction, baseline pain score, and needle
localization on pain scores baseline-corrected during the first 5 min postinjection. The diamonds represent mean predicted pain scores for each
injection agent with corresponding standard deviation
TABLE 2 Change in VAS pain scores over the 5-min postinjection
period
Time (min) Change in pain (mm)* Difference p value**
fTcSC TcTM
1 15.7 ± 5.3 0.5 ± 5.5 15.2 \ 0.001
2 11.5 ± 4.3 0.2 ± 4.4 11.3 0.001
3 7.3 ± 3.7 -0.1 ± 3.8 7.5 0.013
4 3.1 ± 3.6 -0.5 ± 3.7 3.6 0.32
5 -1.1 ± 4.1 -0.8 ± 4.2 -0.3 0.92
fTcSC filtered Technetium-99m Sulfur Colloid; TcTM Technetium-
99m Tilmanocept; VAS visual analogue scale
* Mean ± standard deviation; ** adjusted p value by Holm–Bon-
ferroni method
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anesthetic creams; however, patients were not asked about
their pain until 2–4 days after the procedure. Despite the
benefit of either a preinjection lidocaine injection or lido-
caine-TcSC solution, neither practice has been universally
accepted or adopted likely due to the increased work for the
patient or additional preparation for the clinical treatment
team.
It is unclear how fTcSC induces significantly more pain
than TcTM at the injection site. The pH of the study agents
does not appear to be a factor in the cause of pain as the pH of
both study agents was 6.0. Additionally, the Stojadinovic
study found that pain scores did not differ when they altered
the pH of the injected TcSC agent.2 In our study, TcSC was
filtered with a 100-nm porous filter and the average diameter
of injected TcTM was 7 nm.4 The dermis receives distal
terminations of Ab and Ad myelinated fibers. These fibers
transfer mechanical stimuli from corpusculated receptors
(Ab) and painful stimuli elicited in free nerve endings
(Ad).13 The larger particle size of the fTcSC may increase the
stretch on nociceptive pain receptors in the dermis leading to
an intensified pain experience.
Previous literature supports the effectiveness of TcTM as
a SLN mapping agent in breast, melanoma, and head and
neck cancers.6,7,14–16 Our trial demonstrates that patients
experience significantly less pain with TcTM compared with
fTcSC when standard preparations are injected into the
breast for the purpose of SLN mapping. Thus, TcTM may be
a more ideal diagnostic radiopharmaceutical, because it
minimizes patient discomfort while allowing for effective
SLN mapping. Whereas our study only evaluated injection of
the agent in the breast, the decreased pain effect may be even
more pronounced and desirable when injecting sensitive
areas such as the face, mouth, or genitalia as in SLN mapping
for other types of cancer. Further study is needed to examine
other differentiating factors between the two agents such as
cost, availability, and overall efficacy.
There are a few limitations to this trial. First, not all
patients received preoperative needle localization. How-
ever, in our mixed effects model, neither preoperative
baseline pain nor undergoing needle localization signifi-
cantly affected pain score change from baseline.
Additionally, while an intradermal radiopharmaceutical
injection was used throughout, the location on the breast
was not standardized. Strengths of our study include its
randomized, prospective nature, the blinding of the patient
and injecting physician to the injected study agent, and use
of highly verified pain questionnaires.
CONCLUSIONS
Injection with fTcSC causes significantly more pain
during the first 3 min after radiopharmaceutical injection
compared with TcTM in women undergoing lym-
phoscintigraphy for breast cancer.
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